Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TAVR is Ready for Most Low-risk Patients
Author(s): Ahmad Jabri , Anas Alameh , Gennaro Giustino , et al Added: 9 months ago

Intervention

Vascular Disease and Surgery
EASD 23: Epidemiologic Trends & Disparities in Diabetes Risk Among LGBTQ+ Population
Author(s): Carl Streed Added: 1 year ago
EASD 2023 – Dr Carl G Streed (Boston University School of Medicine, US) joins us to summarise healthcare disparities among the LGBTQ+ population.In this interview, Dr Streed discusses the available evidence and explains the minority stress model. This model suggests that experiences of discrimination and stress contribute to worse health outcomes in the LGBTQ community. This can lead to mental… View more

Demographic

Prevention & Chronic Conditions
ESCHFA25: FINEARTS-HF: Finerenone Risk-Benefit Across Kidney Function
Author(s): Safia Chatur Added: 4 weeks ago
ESC HF 25 - In a FINEARTS HF post-hoc analysis, the relative and absolute effects of finerenone relative to placebo did not significantly differ across kidney function.We are joined by Dr Safia Chatur (Mass General Cardiology, US) to discuss key findings from the FINEARTS-HF trial. This Phase 3 study evaluated the effect of finerenone versus placebo on cardiovascular death and total heart failure… View more

Cardiovascular Renal Metabolic

Heart Failure
ACC 23: Inflammatory Risk from Statin-Treated Patients
Author(s): Paul M Ridker Added: 1 year ago
ACC.23/WCC - We are joined by Dr Paul Ridker (Brigham and Women’s Hospital, US) to discuss the findings from a collaborative analysis of 31,197 patients to assess inflammatory risk in statin-treated patients. The PROMINENT, REDUCE-IT and STRENGTH trials were each large contemporary trials which implemented guideline-directed medical therapy, the findings of which were pooled in this study. The… View more

Prevention & Chronic Conditions
AHA 23: The ORFAN Study
Author(s): Charalambos Antoniades Added: 1 year ago
AHA 23 — In this brief interview, we are joined by Prof Charalambos Antoniades (Oxford University, UK) to discuss the ORFAN trial, sponsored by the University of Oxford.ORFAN is a prospective, multicenter, observational study that collected CT scans, biological material and outcomes data to develop and validate biomarkers of cardiometabolic risk. The registry included 250000 unselected… View more

Digital Health

Prevention & Chronic Conditions
Author(s): Owais Dar , Espeed Khoshbin Added: 7 months ago
Heart transplantation and left ventricular assist devices (LVADs) are crucial options for patients with advanced heart failure, but determining the right timing for intervention is key to optimizing outcomes. This webinar, moderated by Dr Owais Dar from the Royal Brompton and Harefield Hospitals, will explore the decision-making process behind patient referrals, weighing the benefits and risks of… View more

Heart Failure
Timing of Heart Transplantation & LVADs
Author(s): Espeed Khoshbin , Owais Dar Start date: Nov 05, 2024
Heart transplantation and left ventricular assist devices (LVADs) are crucial options for patients with advanced heart failure, but determining the right timing for intervention is key to optimizing outcomes. This webinar, moderated by Dr Owais Dar from the Royal Brompton and Harefield Hospitals, will explore the decision-making process behind patient referrals, weighing the benefits and risks of… View more

Heart Failure
Arrhythmias and Sudden Death: What is New in HCM?
Author(s): Deepthi Rajan , Christopher Ryan Zörner , Morten Lock Hansen , et al Added: 2 months ago

Heart Failure

Prevention & Chronic Conditions
EASD 24: Prespecified Analysis from the SELECT Trial
Author(s): Helen Colhoun Added: 8 months ago
EASD 24 - We are joined by Dr Helen Coulhoun (University of Edinburgh, UK) to discuss the key findings of a prespecified analysis of the SELECT trial, which investigated the effectiveness of semaglutide in reducing major cardiac events in the presence of impaired kidney function in patients with overweight and obesity.Findings showed that participants in the study with reduced eGFR and/or… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Obesity, Cardiac MRI Structure and Non-ischaemic Cardiomyopathy
Author(s): Long Peng , Tao Zeng , Enxi Quan , et al Added: 1 month ago

Cardiovascular Renal Metabolic

Heart Failure